CD8A and neoplasm: Research has shown that the cross-priming of cDC1 is not only necessary for starting CD8+ T-cell responses as tumors progress, but it also has a pivotal role in the reactivation of tumor-specific CD8+ T cells through immunotherapy, leading to tumor shrinkage [129].